BAT CEO Denies Moving Listing to New York

BAT by 2FIRSTS.ai
Mar.18.2024
BAT CEO Denies Moving Listing to New York
British American Tobacco CEO Tadeu Marroco denies plans to move the company's listing from London to New York.

According to a report from the UK's Financial Times, Tadeu Marroco, the CEO of British American Tobacco, has denied the idea of moving the company's listing from London to New York, calling it a "distraction." Previously, the top ten shareholders who were pushing for this change have sold their stakes in the tobacco company.

 

Maroko told the Financial Times that the change of listing venue "will cause a lot of disruption internally," and he is "uncertain if its benefits are as obvious as some people suggest.

 

Last year, Rajiv Jain, Chairman and Chief Investment Officer of the US investment group GQG Partners with $105 billion in assets, urged British American Tobacco to switch its primary listing and clashed with management over the decision to suspend the company's stock buyback program.

 

According to two sources familiar with the matter, GQG sold its 4% stake in British American Tobacco last July because they refused to move and leverage the larger pool of capital in the US, particularly in tobacco stocks. In Europe, an investment environment dominated by ESG considerations means that almost no capital is willing to invest in the tobacco industry.

 

When asked whether he would consider changing the listing location during his tenure, Maroko said, "I believe we should not focus on this issue during this period.

 

He added that there are "many other things" he needs to do, including income in the United States and new products. "There is no indication that... going to the United States is a certainty."

 

He acknowledged that the London capital market is working hard to attract and retain listed companies, but he mentioned the advantages of staying in the UK for investors. Companies that have already moved their main listing venues to the United States include building materials group CRH, packaging company Smurfit Kappa, and gambling group Flutter.

 

Marroco stated, "If you hold shares in a British (listed) company and are overseas, you do not have to pay withholding tax on dividends, unlike in the United States."

 

He said, "I hope that within 10 years, we no longer have to have these discussions." "The reason why there is such a high level of emotions today is due to the frustration caused by some people leaving."

 

For investors, the main reason they are attracted to invest in tobacco stocks is the capital return from dividends and stock buybacks. One of the biggest active investors in British American Tobacco is Spring Mountain Investments, which is an investment vehicle of Kenneth Dart, a billionaire from the Cayman Islands and one of the world's largest foam cup manufacturers.

 

British American Tobacco announced this month that it will use the proceeds from the sale of a portion of its shares in Indian conglomerate ITC for £1.7 billion to restart its stock buyback program, starting with a £700 million buyback this year.

 

Marroco stated, "For me, the most important thing is the restart of repurchases, which should be a consistent feature of our capital allocation."

 

British American Tobacco is facing challenges in reversing the decline in tobacco sales in the United States, its largest market. This is due to people turning to cheaper brands and alternative tobacco products, in which the company is lagging behind the highly successful PMI, whose IQOS heated tobacco product has been very successful.

 

British American Tobacco's goal is to have 50% of its revenue come from alternative products by 2035, such as its Vuse e-cigarette and Glo heated tobacco devices.

 

Marroco acknowledged that English-American Tobacco "started late in the heated tobacco products field," but he stated that due to the company's market share in the US, they have the ability to catch up. "We have a large business in the US that can be used to sell (new products)."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
China-based Shenzhen Huabao Collaborative Innovation Technology Research Institute Co., Ltd. has filed a patent application for a nicotine-ascorbic acid cocrystal, exploring a new solid-state form of nicotine. The patent proposes applications across e-liquids, heated tobacco sticks, oral tobacco, chewing tobacco and snuff. In nicotine pouch tests disclosed in the filing, cocrystal formulations showed less than a 6% decline in nicotine content after three months of accelerated storage and a release profile combining early-stage release with sustained delivery over 60 minutes. The filing reflects exploration of nicotine forms beyond conventional nicotine base and nicotine salts.
Aug.13
China’s Jinhua Tobacco Launches CNY 2.7 Million Procurement for E-Cigarette Violation Lead Monitoring Services
China’s Jinhua Tobacco Launches CNY 2.7 Million Procurement for E-Cigarette Violation Lead Monitoring Services
Jinhua Tobacco, a municipal tobacco company in China’s Zhejiang province, has launched a public tender for e-cigarette-related violation lead monitoring and consulting services. The project is valued at CNY 2.7 million and covers data resource integration and analytical consulting services for 36 months from contract signing. The procurement reflects the use of external data and analysis services to support local tobacco companies’ market oversight activities related to e-cigarettes.
Aug.07
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
CCPIT Says Trade Friction Index for China-Related Electronics Sector Remains High, With Vape Products Among Areas of Focus
CCPIT Says Trade Friction Index for China-Related Electronics Sector Remains High, With Vape Products Among Areas of Focus
China Council for the Promotion of International Trade (CCPIT) held its July regular press conference on July 31, 2026, releasing the May 2026 Global Economic and Trade Friction Index. CCPIT spokesperson Yang Fan said the global trade friction index stood at 95 in May, remaining at a medium-to-high level. By industry, the electronics sector recorded the highest trade friction index among 13 monitored industries. In China-related trade frictions, the index stood at 93, with electronics products including drones, chips and vape products among areas where friction remained elevated.
Aug.03
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
A new expert paper in JAMA urges U.S. clinicians to include nicotine e-cigarettes in smoking-cessation discussions, citing higher quit rates than nicotine replacement therapy. It also stresses that products must deliver enough nicotine to replace cigarettes, dual use should be brief, and complete switching is the goal. 2Firsts argues the recommendations matter beyond clinics: public-health professionals should reassess relative risk, regulators should preserve sufficient product appeal for adult smokers, and manufacturers should focus on helping users quit cigarettes more sustainably.
SCIENCE
Aug.03 by 2Firsts Perspectives